Journal Articles on Mesothelioma: September, 2006
September 15th, 2006. Surgical staging and treatment in malignant pleural mesothelioma
Results: In this series two complications were reported: one diaphragmatic hernia and one postpneumonectomy empyema which were solved with re operation; one single case of peri-operative mortality was reported. 5-Years survival data will be available soon. Videos of every procedure will be shown.
September 13th, 2006. Cytogenetic and molecular genetic changes in malignant mesothelioma
Ongoing studies are already applying high-throughput genomic profiling methods in MM. Genetic alterations observed in MM may be useful in differential diagnosis between lung cancer and MM, as diagnostic markers or therapeutic targets, and as indicators of premalignancy for primary prevention and health surveillance.
September 13th, 2006. High-resolution analysis of 9p loss in human cancer cells using single nucleotide polymorphism-based mapping arrays
In the latter cell line, allele analysis revealed that virtually all SNPs for chromosome 9 were homozygous, suggestive of uniparental disomy. These findings demonstrate the utility of SNP-based mapping arrays for high-resolution analysis of genomic imbalances in cancer cells.
September 13th, 2006. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters
Significantly lower amounts of asbestos were sufficient to cause MM in animals infected with SV40. Our results indicate that mineral fibers and viruses can be cocarcinogens and suggest that lower amounts of asbestos may be sufficient to cause MM in individuals infected with SV40.
September 12th, 2006. Human malignant mesothelioma: Molecular mechanisms of pathogenesis and progression
Abstract The continuing identification and elucidation of the molecular defects involved in mesothelioma pathogenesis and progression should lead to better disease control and greater therapeutic options in the near future. Goal of this review article is to summarize the most recent advances in molecular pathogenesis of mesothelioma and discuss possible therapeutic implications of these findings.
September 12th, 2006. Cardiac tamponade complicating trimodal therapy for malignant mesothelioma
We report here a case of hypotension secondary to tension hydrothorax in which echocardiography and hemodynamic monitoring demonstrated evidence of tamponade physiology. Thoracentesis was lifesaving.
September 11th, 2006. Malignant mesothelioma masquerading as a multinodular bronchioloalveolar cell adenocarcinoma with widespread pulmonary nodules
Ultrastructurally, they had very long and abundant, slender microvilli typical of a malignant mesothelioma. This is the first example of a mesothelioma masquerading as a bronchioloalveolar carcinoma.
September 11th, 2006. Exclusive intrapulmonary lepidic growth of a malignant pleural mesothelioma presenting with pneumothorax and involving the peritoneum
The patient subsequently experienced acute abdominal pain with peritonitis and intestinal occlusion by peritoneal mesothelioma. The morphologic clues leading to the correct diagnosis of mesothelioma with prominent intrapulmonary growth are briefly discussed.
September 8th, 2006. Asbestos-related disease from recycled hessian superphosphate bags in rural Western Australia
Conclusions: It appears that the use of recycled hessian bags for the fertiliser industry was endemic in the State during the period 1943-66. It is possible that many farmers and their families have had similar exposure to asbestos. Implications: The risk of developing an asbestos-related disease is not restricted to any specific social or employment groups within the Australian community.
September 6th, 2006. Radical surgery for mesothelioma
The diaphragm is lowered to facilitate radiotherapy. Chemotherapy may be performed postoperatively.
September 6th, 2006. A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions
Conclusions: We have developed a test that is able to distinguish between lung adenocarcinoma and mesothelioma in cells collected from pleural effusions.
September 6th, 2006. Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma
This protein may regulate proliferation linked with differentiation toward epithelioid morphology in mesothelial cells. Expression of the protein may be a prognostic indicator for patents with malignant mesothelioma.
September 6th, 2006. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress
This offers a possible mechanism of action of selenite treatment. Our findings suggest that selenite is a promising new drug for the treatment of malignant mesothelioma.
September 6th, 2006. RB and cell cycle progression
Gene inactivation of pRB through chromosomal mutations is one of the principal reasons for retinoblastoma tumor development. Functional inactivation of pRb by viral oncoprotein binding is also shown in many neoplasias such as cervical cancer, mesothelioma and AIDS-related Burkitt's lymphoma.
September 6th, 2006. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma
Conclusions: NVP-AEW541 has a concentration-dependent inhibitory effect on mesothelioma cells in culture. NVP-AEW541 acts by inhibition of IGF-1R phosphorylation. Inhibition effects phosphorylation of downstream mediators in a dose-dependent fashion. Inhibition of the IGF pathway decreases viability of mesothelioma cell culture. Further evaluation of NVP-AEW541, and other selective IGF-1R inhibitors, may play an important role in multimodal treatment of malignant mesothelioma.
|
|  |
